NASDAQ:CBIO
Delisted
Catalyst Biosciences Stock News
$0.511
+0 (+0%)
At Close: Dec 14, 2023
Becton Dickinson (BDX) Down 5.2% Since Last Earnings Report: Can It Rebound?
04:31pm, Saturday, 07'th Mar 2020
Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst
05:12am, Friday, 06'th Mar 2020
Chardan Capital analyst Gbola Amusa reiterated a Hold rating on Voyager Therapeutics (VYGR) today and set a price target of $20.00. The company's shares
Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst
05:12am, Friday, 06'th Mar 2020
Chardan Capital analyst Gbola Amusa reiterated a Hold rating on Voyager Therapeutics (VYGR – Research Report) today and set a
Amicus (FOLD) Receives a Rating Update from a Top Analyst
05:10am, Thursday, 05'th Mar 2020
In a report released today, Gbola Amusa from Chardan Capital reiterated a Hold rating on Amicus (FOLD), with a price target of $12.50. The company's
uniQure (QURE) Receives a Rating Update from a Top Analyst
03:26pm, Tuesday, 03'rd Mar 2020
Chardan Capital analyst Gbola Amusa reiterated a Buy rating on uniQure (QURE) today and set a price target of $105.00. The company's shares closed last
uniQure (QURE) Receives a Rating Update from a Top Analyst
03:26pm, Tuesday, 03'rd Mar 2020
Chardan Capital analyst
Gbola Amusa
reiterated a
Buy
rating on uniQure (
QURE
–
Research Report
) today and set a price target of
$105.00
. The company’s shares closed last Monday at $56.50.
Accor
C16 Biosciences Company Profile: Valuation & Investors | PitchBook
07:58pm, Monday, 02'nd Mar 2020
Information on valuation, funding, cap tables, investors, and executives for C16 Biosciences. Use the PitchBook Platform to explore the full profile.
Critical Survey: Pulse Biosciences (NASDAQ:PLSE) versus RA Medical Systems (NASDAQ:RMED)
07:48am, Saturday, 29'th Feb 2020
Pulse Biosciences (NASDAQ:PLSE) and RA Medical Systems (NYSE:RMED) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength o
Oppenheimer Maintains Their Buy Rating on Athenex (ATNX)
07:34pm, Thursday, 27'th Feb 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Athenex (ATNX) today and set a price target of $23.00. The company's shares closed last
Oppenheimer Maintains Their Buy Rating on Athenex (ATNX)
07:33pm, Thursday, 27'th Feb 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Athenex (ATNX – Research Report) today and set a price target
Wall Street Analysts Are Bullish on Top Healthcare Picks
08:43am, Thursday, 27'th Feb 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Novavax (NVAX) and Intercept Pharma (ICPT) with bullish
Catalyst Biosciences to Present at the Cowen Healthcare Conference
01:00pm, Monday, 24'th Feb 2020
Catalyst Biosciences, Inc. (CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will present a corporate overview at the Cowen Healthcare C
Oppenheimer Reaffirms Their Buy Rating on Vericel (VCEL)
11:19pm, Sunday, 23'rd Feb 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Vericel (VCEL – Research Report) today and set a price target
Catalyst Biosciences Reports Fourth Quarter and Full-Year 2019 Operating & Financial Results and Provides a Corporate Update
09:05pm, Thursday, 20'th Feb 2020
Presented positive clinical and pre-clinical data from its MarzAA and DalcA hemophilia programs Announced a global license and collaboration agreement with Biogen to develop.
Analysts Offer Insights on Healthcare Companies: Molecular Templates (MTEM), Atricure (ATRC) and Fate Therapeutics (FATE)
10:06pm, Wednesday, 19'th Feb 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Molecular Templates (MTEM), Atricure (ATRC) and Fate
